Actions and Spectrum:
anagrelide’s exact method of action is unknown, although it is thought to function by blocking the activity of the enzyme cyclic AMP phosphodiesterase III (PDE III), which breaks down cyclic AMP. This causes a rise in intracellular cyclic AMP, which in turn causes platelet and megakaryocyte production to fall.
anagrelide is a selective inhibitor of megakaryocyte maturation and platelet formation in terms of its spectrum. Both coagulation factors and other blood cells are not significantly impacted.
